Vor Biopharma prices $100 million share offering as partner RemeGen reports strong Phase 3 results for telitacicept in IgA ...
Multiple Late-Stage Data Readouts Reinforce Telitacicept’s Broad Potential Across Autoimmune DiseasesExpansion of Executive ...
Fintel reports that on November 14, 2025, HC Wainwright & Co. maintained coverage of Vor Biopharma (NasdaqGS:VOR) with a Buy ...
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gr ...
Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it ...
The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $40.54 / share. This is a decrease of ...
Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.
Telitacicept is a dual inhibitor of both B-lymphocyte stimulator and a proliferation-inducing ligand, cytokines that promote B cell survival and production of pathogenic galactose-deficient IgA1.
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial in China that enrolled 318 adult patients with IgAN at high risk of progression who had received stable ...
According to The Campbell’s Company’s 2025 State of the Sides report, 63% of Americans prefer sides dishes over the entree at ...
Turkey is the star of a Thanksgiving table, but let's be honest, it's the savory side dishes that make the holiday dinner ...
Nestlé Accused Of Selling High Sugar Content In Africa. Swiss NGO Public Eye has again accused the Swiss food giant Nestlé of selling over-sugared baby food in Africa. This content was published on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback